US Stock MarketDetailed Quotes

TARS Tarsus Pharmaceuticals

Watchlist
  • 43.795
  • -1.745-3.83%
Trading Feb 25 12:16 ET
1.68BMarket Cap-14.27P/E (TTM)

Tarsus Pharmaceuticals Key Stats

Tarsus Pharmaceuticals Q4 2024 Estimates Date

Currency:USDFeb 25, 2025

Estimate YoY
Revenue
58.80M
+349.70%
EPS
-0.67
+48.53%
Strong Buy

Feb 25, 2025

Tarsus Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 73.778M--
--2025/Q1-- / 64.451M--
Feb 25, 20252024/Q466.408M / 58.803M--
Nov 13, 20242024/Q348.118M / 43.177M--
Aug 8, 20242024/Q240.813M / 32.048M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 73.778M--
--2025/Q1-- / 64.451M--
Feb 25, 20252024/Q466.408M / 58.803M--
Nov 13, 20242024/Q348.118M / 43.177M--
Aug 8, 20242024/Q240.813M / 32.048M--

Unlock Free Earnings Estimates

Tarsus Pharmaceuticals Earnings Reports

Read more

Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Feb 25, 2025

Strong Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data